Drugs that contain Semaglutide

1. List of Ozempic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8672898 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 28 days ago)

US9486588 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 28 days ago)

US6899699 NOVO Automatic injection device with reset feature
Jan, 2022

(1 year, 28 days ago)

US8579869 NOVO Needle mounting system and a method for mounting a needle assembly
Jun, 2023

(4 months from now)

US7762994 NOVO Needle mounting system and a method for mounting a needle assembly
May, 2024

(1 year, 3 months from now)

US8114833 NOVO Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Aug, 2025

(2 years from now)

US8684969 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US11446443 NOVO Injection device with torsion spring and rotatable display
Oct, 2025

(2 years from now)

US9616180 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US9861757 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US9108002 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US10357616 NOVO Injection device with an end of dose feedback mechanism
Jan, 2026

(2 years from now)

US10376652 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11311679 NOVO Automatic injection device with a top release mechanism
Jan, 2026

(2 years from now)

US11097063 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

US8920383 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US9775953 NOVO Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Jul, 2026

(3 years from now)

US10220155 NOVO Syringe device with a dose limiting mechanism and an additional safety mechanism
Jul, 2026

(3 years from now)

USRE46363 NOVO Dial-down mechanism for wind-up pen
Aug, 2026

(3 years from now)

US9687611 NOVO Injection device with torsion spring and rotatable display
Feb, 2027

(4 years from now)

US9457154 NOVO Injection device with an end of dose feedback mechanism
Sep, 2027

(4 years from now)

US9132239 NOVO Dial-down mechanism for wind-up pen
Feb, 2032

(9 years from now)

US10335462 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Jan 16, 2023
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Dosing Schedule (D) Mar 28, 2025

NCE-1 date: December, 2021

Market Authorisation Date: 05 December, 2017

Treatment: A method of treating type 2 diabetes comprising administering semaglutide once weekly in a amount of 1.0 mg to a subject in need thereof; Ozempic is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of OZEMPIC before it's patent expiration?
More Information on Dosage

2. List of Rybelsus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9278123 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US11382957 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10960052 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl) amino) caprylic acid
Dec, 2031

(8 years from now)

US10086047 NOVO Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid
Dec, 2031

(8 years from now)

US10933120 NOVO Compositions of GLP-1 peptides and preparation thereof
Mar, 2033

(10 years from now)

US10278923 NOVO Oral dosing of GLP-1 compounds
May, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M Jan 16, 2023
New Product (NP) Sep 20, 2022
New Chemical Entity Exclusivity (NCE) Dec 5, 2022

NCE-1 date: December, 2021

Market Authorisation Date: 20 September, 2019

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

More Information on Dosage

3. List of Wegovy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8536122 NOVO Acylated GLP-1 compounds
Mar, 2026

(3 years from now)

US8129343 NOVO Acylated GLP-1 compounds
Dec, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003 NOVO Use of long-acting GLP-1 peptides
Jun, 2033

(10 years from now)

US10888605 NOVO GLP-1 compositions and uses thereof
Aug, 2038

(15 years from now)

US11318191 NOVO GLP-1 compositions and uses thereof
Feb, 2041

(18 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 5, 2022
New Product (NP) Jun 4, 2024

NCE-1 date: December, 2021

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic